alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 26–50 of 120 studies by Jack CR marked Peer-reviewed (page 2 of 5) · 30,980 in the whole library · How the 0–100 score works

Download bibliography of these 120 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Other authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 16,452 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort

✓ Peer-reviewed alzhub usefulness score 64 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2016-07-18

Plasma tau is associated with cortical thickness and memory performance. 3 key findings →

Design: longitudinal study Participants: 378 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study

✓ Peer-reviewed alzhub usefulness score 64 out of 100. The Lancet. Neurology 2015-11-18

Our transition rates suggest that brain ageing is a nearly inevitable acceleration toward worse biomarker and clinical states. 5 key findings →

Design: cross-sectional Participants: 4,049 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span

✓ Peer-reviewed alzhub usefulness score 63 out of 100. JAMA neurology 2015-05-01

Overall, memory worsened from age 30 years through the 90s. The HVa worsened gradually from age 30 years to the mid-60s and more steeply beyond that age. 5 key findings →

Design: cross-sectional Participants: 1,246 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Brain : a journal of neurology 2010-10-08

We used a new method of pooling cerebrospinal fluid Aβ42 and Pittsburgh compound B positron emission tomography measures to produce equivalent measures of brain Aβ load from either source and analysed the results using multiple imputation methods. 3 key findings →

Participants: 165 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition

✓ Peer-reviewed alzhub usefulness score 63 out of 100. NeuroImage 2009-04-01

Tensor-based morphometry can recover three-dimensional longitudinal brain changes over time by nonlinearly registering baseline to follow-up MRI scans of the same subject. 2 key findings →

Design: longitudinal study Participants: 20 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Neurobiology of aging 2007-04-23

The vitamin E and donepezil trial for the treatment of amnestic mild cognitive impairment (MCI) was conducted at 69 centers in North America; 24 centers participated in an MRI sub study. 2 key findings →

Participants: 131 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Neurology 2003-01-01

The consistency of MRI measurements obtained across sites, and the consistency between the multisite milameline data and that obtained in prior single-site studies, demonstrate the technical feasibility of using structural MRI measures as a surrogate endpoint of disease progression in therapeutic trials. 1 key finding →

Participants: 362 Evidence: high

Full summary, score breakdown and related studies → Original source

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2011-04-21

The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of revising the 1984 criteria for Alzheimer's disease (AD) dementia. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Annals of neurology 2012-04-09

This cross-sectional evaluation of the NIA-AA criteria for preclinical AD indicates that the 1-3 staging criteria coupled with stage 0 and SNAP categories classify 97% of CN subjects from a population-based sample, leaving only 3% unclassified. 2 key findings →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2018-10-13

(1) Data-driven AD progression models supported multifactorial interactions rather than a linear cascade of events. 4 key findings →

Design: longitudinal study Evidence: high

Full summary, score breakdown and related studies → Original source

Cerebral Microbleeds, CSF p-Tau, and Cognitive Decline: Significance of Anatomic Distribution

✓ Peer-reviewed alzhub usefulness score 60 out of 100. AJNR. American journal of neuroradiology 2015-07-30

The distribution of microbleeds revealed different associations with amyloid-β and phosphorylated tau 181 protein levels and cognition. 5 key findings →

Design: longitudinal study Participants: 626 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Neurology 2004-02-01

These data support the use of rates of change from serial MRI studies in addition to standard clinical/psychometric measures as surrogate markers of disease progression in AD. 1 key finding →

Participants: 55 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Progressive Tau Accumulation in Alzheimer Disease: 2-Year Follow-up Study

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2019-03-29

In contrast to no change in global cortical SUVR in the CU- and CU+ groups during the 2-y period, global cortical SUVR increased by 0.06 (2.9%) in the MCI+ group and 0.19 (8.0%) in the DEM+ group at follow-up. 5 key findings →

Design: cross-sectional Participants: 107 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Neurology 2002-03-01

Individuals with an isolated pathologic diagnosis of AD, hippocampal sclerosis, frontotemporal degeneration, and neurofibrillary tangle--only degeneration usually had substantial hippocampal atrophy, while those with changes of typical aging did not. 2 key findings →

Participants: 67 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Neurology 1997-09-01

Magnetic resonance imaging (MRI)-based volumetric measurements of medial temporal lobe (MTL) structures can discriminate between normal elderly control subjects and patients with Alzheimer's disease (AD) of moderate to advanced severity. 1 key finding →

Participants: 94 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events